Our company

SCINTOMICS is a leading provider of innovative tracer technologies in the field of molecular imaging and radioligand therapy in oncology. We are committed to targeted diagnostics and therapeutics, so called THERANOSTICS, and corresponding radiopharmaceutical technologies. Our strong focus towards personalized cancer care is reflected by an exceptional portfolio of innovative tracer technologies and the clinical development of Theranostic through subsidiaries, joint ventures, alliances and licenses.


Proven track records

SCINTOMICS was founded in 2006 with the aim of developing widely applicable and easy-to-use synthesis modules for radiopharmaceuticals, and providing this powerful instrumentation to nuclear medicine clinics and research facilities for the fully automated production of radiopharmaceuticals all around the world. By installation of hundreds of Synthesis Modules to Customers all over the world, we succeeded in building up a strong medical and scientific network, while always adhering to our principle: Promising the possible, building and strengthening the reputation through trust.

As one of the leading suppliers of automated synthesizers for theranostics, we recognized very early an innovation gap which hindered or even prevented the conversion of promising new radiopharmaceuticals into clinical development.

Learn more about how Radio-Theranostics can improve cancer treatment

Scintomics video still thumbnail.jpg

Rich and unique portfolio

In 2010 SCINTOMICS expanded the scope of its activities and started to promote targeted radiopharmaceuticals in the oncological field, such as PSMA I&T, HA-DOTATATE, Avebetrin, Pentixafor and other radiopharmaceuticals by offering dedicated solutions for in-house production of such tracers. SCINTOMICS further expanded by building up a substantial portfolio of proprietary radiopharmaceuticals, such as rhPSMA, siPSMA, PSMA PNT2002 and rhTATE to mention only a few.  

Scintomics Mission

Bridging preclinical research and clinical development to accelerate the clinical implementation of unique cancer diagnostics and therapeutics for the long term benefit of cancer patients. 



Scintomics Molecular – Applied Theranostics Technologies

As a growing player in the radiopharmaceutical business, a subsidiary of SCINTOMICS, Scintomics Molecular – Applied Theranostics Technologies (ATT) was founded in 2018. It continues, in an independent manner, the Automation & Precursor business segment, that is the sale of proprietary and non-proprietary labeling precursors and the distribution of corresponding fully automated synthesizers and consumables.

Visit website


Blue Earth Diagnostics

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Visit website
Point Biopharma Logo.jpg



POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radio-pharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like Actinium-225 and Lutetium-177.

Visit website
BayPAT logo.jpg



Bayerische Patentallianz GmbH (BayPAT) is the central patent and marketing agency to foster technology transfer of Universities, University Hospitals and Universities of Applied Sciences in Bavaria since 2007. With many years of experience and excellence in patenting and licensing of new technologies, BayPAT commercializes innovations from 33 research institutes. Connecting science and economy, BayPAT strives to make the valuable inventions from its clients commercially exploitable by industry.

Visit website

Our milestones

Below you can find an overview of our milestones since the foundation of Scintomics.

POSLUMA_logo.JPG 2023

Posluma Market Approval

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Blue-Earth 1.svg 2021

Blue Earth Diagnostics

Licensing agreement with Blue Earth Diagnostics for therapeutic rhPSMAs.

PentixaPharm thumbnail news.jpg 2021

Aquistion of PentixaPharm by Eckert & Ziegler

Acquisition of the majority of PentixaPharm by Eckert & Ziegler Strahlen- und Medizintechnik AG

att.png 2020

SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (att)

Scintomics conducted a reorganization to focus on the clinical development of the company’s projects. Subsidiary Scintomics ATT takes over module, consumable and precursor business.

Point_logo.png 2019

Point Biopharma

Licensing agreement with POINT Biopharma for therapeutic PSMA (world - except Asia).

PentixaPharm thumbnail news.jpg 2019

Foundation of PentixaPharm

A joint Venture of SCINTOMICS and 1717LSV on CXCR4 ligands

technische-universitat-munchen-tum-logo.png 2019

TUM Award

Scintomics receives TUM Presidential Entrepreneurship Award.

att.png 2018


Foundation of Scintomics ATT as subsidiary of Scintomics

Blue-Earth 1.svg 2018

Blue Earth Diagnostics

Licensing agreement with BlueEarth Diagnostics for diagnostic rhPSMA.

bayerische_patentallianz_logo.png 2017

Next Generation CXCR4 compounds

Licensing of CXCR4 follow-up technology from TUM / BayPAT.

bayerische_patentallianz_logo.png 2017

rhPSMA technology

Licensing of rhPSMA technology from TUM / BayPAT.

bayerische_patentallianz_logo.png 2015

Pentixther for therapy

The CXCR4 therapeutic tracer Pentixather is bought from TUM / BayPAT.

bayerische_patentallianz_logo.png 2015


IMAZA (Theridat) as a promising theranostic tool for adrenocortical tumors is licensed from UKW / BayPAT.

bayerische_patentallianz_logo.png 2013

18F-Labeling Technology

18F-Labeling by direct elution without time consuming azeotropic drying is now possible with licensed IP from TUM/BayPat.

bayerische_patentallianz_logo.png 2013

Acquistion of radiolabeled RGD peptides

TRAP(RGD)3 (Avebetrin) technology is bought from TUM / BayPAT

bayerische_patentallianz_logo.png 2013

Pentixafor is born

Scintomics buys the IP of CXCR4 imaging compounds (Pentixafor) from TUM / BayPAT

logo-scintomics.svg 2010


Installation of >150 production systems worldwide.

logo-scintomics.svg 2010

Introduction of GMP compliant GRP MODULES

Start of GRP Module Series.

logo-scintomics.svg 2006


Foundation of Scintomics GmbH by Prof. H.J. Wester.